ORGS · As filed with the SEC
Orgenesis income statement, by fiscal year
The statement as Orgenesis presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Comprehensive Loss (Income) · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 |
|---|---|---|---|---|---|
| Customer D (United States) | 1,035 | 530 | 34,741 | 31,646 | 6,177 |
| Revenue | — | — | 1,284 | 3,856 | 1,475 |
| Total revenues | — | — | 36,025 | 35,502 | 7,652 |
| Nonrelated Party | — | 530 | — | — | — |
| Cost of Revenue | 1,928 | 6,255 | 27,066 | — | — |
| Gross loss | (893) | (5,725) | — | — | — |
| Research and Development Expense | 9,622 | 10,623 | — | 36,644 | 83,986 |
| Amortization of Intangibles | 728 | 721 | 911 | 948 | 478 |
| Change in Contingent consideration | (4,643) | — | — | — | — |
| Selling, General and Administrative Expense | 14,822 | 35,134 | 15,589 | 14,710 | 18,973 |
| Share in net loss of associated companies | 8 | 734 | 1,508 | — | — |
| Impairment of investment | — | 699 | — | — | — |
| Impairment charges | — | — | 1,061 | — | — |
| Impairment Charges (CF) | 18,338 | — | — | — | — |
| Operating loss | 39,768 | 53,636 | 8,602 | 16,800 | 95,785 |
| Other income, net | — | — | — | (2,278) | (4) |
| Loss (profit) from deconsolidation of OBI, Korea, Belgium, Services and Octomera (see note 3 and note 20) | (4,480) | 5,343 | — | — | — |
| Other income, net | (606) | (4) | (173) | — | — |
| Loss from extinguishment in connection with loans | 5,422 | 283 | 52 | 1,865 | — |
| Credit loss on convertible loan receivable | — | 2,688 | — | — | — |
| Financial expenses, net | 4,508 | 2,499 | 1,971 | 1,292 | 1,061 |
| Share in net loss (income) of associated companies | — | — | — | 272 | (106) |
| Inducement expense on conversion of convertible loans | 4,304 | — | — | — | — |
| Loss before income taxes | 48,916 | 64,445 | 11,960 | 17,951 | 96,736 |
| Income Tax Expense | 97 | 473 | 209 | 108 | (1,609) |
| Net loss from continuing operation | — | — | — | 18,059 | 95,127 |
| Net income from discontinued operations, net of tax | — | — | — | — | (95,706) |
| Net loss | 49,013 | 64,918 | 12,169 | 18,059 | (579) |
| Net Income Attributable to Noncontrolling Interest | — | — | — | (6) | (39) |
| Extraordinary Items | — | — | — | — | (492) |
| Net Income Attributable to Noncontrolling Interest | (848) | (9,557) | 2,720 | — | — |
| Net loss attributable to Orgenesis Inc. | 48,165 | 55,361 | 14,889 | 18,053 | (1,110) |
| Basic and diluted from continuing operation | — | — | — | 0.74 | 4.46 |
| Basic and diluted from discontinued operation | — | — | — | — | (4.75) |
| Basic and diluted | — | — | — | 0.74 | (0.29) |
| Earnings Per Share (Basic) | 11.44 | 1.91 | 0.59 | — | — |
| Earnings Per Share (Diluted) | 11.44 | 1.91 | — | — | — |
| Shares Outstanding | |||||
| Basic and diluted | — | — | — | 24,273,658 | 21,320,314 |
| Basic | 4,210,839 | 29,007,869 | 25,096,284 | — | — |
| Diluted | 4,210,839 | 29,007,869 | — | — | — |
| Comprehensive loss: | |||||
| Net loss from Continuing Operation | — | — | — | 18,059 | 95,127 |
| Net loss income from Discontinued Operation, Net of Tax | — | — | — | — | (95,706) |
| Other Comprehensive (income) loss – Translation adjustment | — | — | — | 541 | (341) |
| Release of translation adjustment due to sale of subsidiary | — | — | — | — | (194) |
| Comprehensive loss (income) | — | — | — | 18,600 | (1,114) |
| Comprehensive loss attributed to non-controlling interests | — | — | — | (6) | (39) |
| Comprehensive loss attributed to non-controlling interests from discontinued operations | — | — | — | — | (492) |
| Net loss | — | — | 12,169 | — | — |
| Other Comprehensive loss – Translation adjustment | (853) | 49 | 477 | — | — |
| Release of translation adjustment due to deconsolidation of Orgenesis Korea and the Belgian Subsidiary in 2024 (Octomera in 2023) | 534 | (384) | — | — | — |
| Comprehensive loss | — | 64,583 | 12,646 | — | — |
| Comprehensive (loss) income attributed to non-controlling interests | — | (9,557) | 2,720 | — | — |
| Comprehensive loss | 48,694 | — | — | — | — |
| Net Income Attributable to Noncontrolling Interest | (848) | — | — | — | — |
| Comprehensive loss attributed to Orgenesis Inc. | 47,846 | 55,026 | 15,366 | 18,594 | (1,645) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.